详细说明
- Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
- Endotoxin Level<0.10 EU per 1 μg of the protein by the LAL method.
- ActivityMeasured by its ability to bind CD155 in a functional ELISA.
- SourceMouse myeloma cell line, NS0-derived
Human DNAM-1/CD226
(Glu19-Asn247)
Accession # Q15762HIEGRMD Human IgG1
(Pro100-Lys330)N-terminus C-terminus - Accession #
- N-terminal Sequence
AnalysisGlu19 - Structure / FormDisulfide-linked homodimer
- Predicted Molecular Mass53 kDa (monomer)
- SDS-PAGE90 kDa, reducing conditions
| 666-DN | | |
| Formulation Lyophilized from a 0.2 μm filtered solution in PBS. | ||
| Reconstitution Reconstitute at 100 μg/mL in sterile PBS. | ||
| Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. | ||
| Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily (1). Mature human DNAM-1 contains a 236 amino acid (aa) extracellular domain (ECD) with two Ig-like C2-set domains and a 61 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, human DNAM-1 shares 50% and 52% aa sequence identity with mouse and rat DNAM-1, respectively. DNAM-1 is expressed on multiple lymphoid and myeloid cells and interacts with CD155/PVR and Nectin-2/CD112 (3, 4). Ligation of DNAM-1 promotes the activation of NK cells, CD8+ T cells, and mast cells (2-6), dendritic cell maturation, megakaryocyte and activated platelet adhesion to vascular endothelial cells, and monocyte extravasation; it inhibits the forrmation of osteoclasts (7-10). Platelet-endothelium interactions mediated by DNAM-1 enable the metastasis of tumor cells to the lung (11). In activated, but not in resting NK, T, and mast cells, the cis association of DNAM-1 with CD18 contributes to the tyrosine and serine phosphorylation of DNAM-1 during activation (6, 9, 12-14).
- References:
- Fuchs, A. and M. Colonna (2006) Semin. Cancer Biol. 16:359.
- Shibuya, A. et al. (1996) Immunity 4:573.
- Bottino, C. et al. (2003) J. Exp. Med. 198:557.
- Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
- Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
- Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
- Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
- Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
- Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
- Tahara-Hanaoka, S. et al. (2006) Blood 107:1491.
- Morimoto, K. et al. (2007) Oncogene July 16 epub.
- Shibuya, K. et al. (1999) Immunity 11:615.
- Shibuya, K. et al. (2003) J. Exp. Med. 198:1829.
- Shibuya, A. et al. (1998) J. Immunol. 166:1671.
- Long Name:DNAX Accessory Molecule 1
- Entrez Gene IDs:10666 (Human); 225825 (Mouse); 307199 (Rat); 102117316 (Cynomolgus Monkey)
- Alternate Names:CD226 antigenplatelet and T cell activation antigen 1; CD226 molecule; CD226; DNAM1; DNAM-1; DNAM1adhesion glycoprotein; DNAM-1DNAX accessory molecule-1; DNAX accessory molecule 1; PTA1; T lineage-specific activation antigen 1 antigen; TLiSA1
400-6226-992